InvestorsHub Logo
Followers 59
Posts 18522
Boards Moderated 0
Alias Born 11/29/2006

Re: None

Tuesday, 10/03/2017 3:01:06 PM

Tuesday, October 03, 2017 3:01:06 PM

Post# of 157
The FDA's Dermatologic and Ophthalmic Drugs Advisory Committee will meet on October 13 to review and discuss Aerie Pharmaceuticals' (AERI -5.5%) New Drug Application seeking approval for Rhopressa (netarsudil ophthalmic solution) to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

The FDA's action date is February 28, 2018.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AERI News